EQT Life Sciences Secures $56 Million to Advance Neuros Medical's Pain Management Technology
On July 9, 2025, EQT Life Sciences announced a pivotal moment in the fight against post-amputation pain by co-leading a $56 million Series D financing round for Neuros Medical, Inc. This U.S.-based medical device company is dedicated to developing groundbreaking solutions for chronic pain that follows amputations.
The funding round, collaborated with the LSP 7 fund, aims to propel the commercialization of Neuros Medical's flagship product, Altius®, which is a direct electrical nerve stimulation system. This innovative therapy has gained FDA approval for treating chronic, intractable post-amputation pain, a condition that significantly affects the lives of amputees. Currently, it is estimated that up to 80% of amputees endure post-amputation pain, which often lacks effective non-opioid treatment alternatives.
David Veino, the President and CEO of Neuros Medical, expressed his enthusiasm about the potential of this funding to enhance the commercial operations of the company and ultimately increase accessibility to this revolutionary treatment. 'We are grateful for the support from EQT and our syndicate partners as we continue our mission to relieve pain and restore life for amputees,' he stated, emphasizing the urgency of addressing this prevalent issue.
The Altius® system stands out as the only FDA-approved solution tailored specifically for post-amputation pain management. It provides patients with on-demand therapy through targeted nerve stimulation, allowing users to control their experience and better manage their pain. The technology not only emphasizes user autonomy but also represents a major step towards improved quality of life for those suffering after losing a limb.
Dr. Fouad Azzam, a Partner in the EQT Life Sciences advisory team, highlighted the crucial role of Neuros Medical in tackling chronic pain management challenges. He acknowledged the company’s commitment to improving the quality of life for amputees and voiced EQT’s pride in partnering with them to bring the Altius® therapy to market.
The funding will facilitate not only the commercialization of Altius® but also further advancements in Neuros Medical's research and development efforts to create more therapeutic solutions. The support from EQT and other partners indicates a growing interest and acknowledgment of the significance of innovative medical technologies aimed at managing chronic pain effectively.
As the medical community continues to seek alternatives to opioid treatments, the potential applications for the technology behind Altius® may expand, giving hope to many individuals struggling with pain following amputations. The successful execution of this financial injection could mark a breakthrough not just for Neuros Medical, but for numerous patients eagerly awaiting effective pain relief options.
With the ever-increasing need for less invasive and non-opioid solutions in healthcare, Neuros Medical positions itself as a frontrunner in creating impactful change within this space. The imminent commercialization of Altius® through the support received could lead to a transformative era in pain management for amputees, ensuring that they can lead more fulfilling lives despite their challenges.
In conclusion, the collaboration between EQT Life Sciences and Neuros Medical signifies a commitment to address an urgent need within the medical field. As funding fuels innovation, the hope is that more patients will soon experience the benefits of advanced therapies, paving the way for a future where pain control is accessible, effective, and life-enhancing.
The funding round, collaborated with the LSP 7 fund, aims to propel the commercialization of Neuros Medical's flagship product, Altius®, which is a direct electrical nerve stimulation system. This innovative therapy has gained FDA approval for treating chronic, intractable post-amputation pain, a condition that significantly affects the lives of amputees. Currently, it is estimated that up to 80% of amputees endure post-amputation pain, which often lacks effective non-opioid treatment alternatives.
David Veino, the President and CEO of Neuros Medical, expressed his enthusiasm about the potential of this funding to enhance the commercial operations of the company and ultimately increase accessibility to this revolutionary treatment. 'We are grateful for the support from EQT and our syndicate partners as we continue our mission to relieve pain and restore life for amputees,' he stated, emphasizing the urgency of addressing this prevalent issue.
The Altius® system stands out as the only FDA-approved solution tailored specifically for post-amputation pain management. It provides patients with on-demand therapy through targeted nerve stimulation, allowing users to control their experience and better manage their pain. The technology not only emphasizes user autonomy but also represents a major step towards improved quality of life for those suffering after losing a limb.
Dr. Fouad Azzam, a Partner in the EQT Life Sciences advisory team, highlighted the crucial role of Neuros Medical in tackling chronic pain management challenges. He acknowledged the company’s commitment to improving the quality of life for amputees and voiced EQT’s pride in partnering with them to bring the Altius® therapy to market.
The funding will facilitate not only the commercialization of Altius® but also further advancements in Neuros Medical's research and development efforts to create more therapeutic solutions. The support from EQT and other partners indicates a growing interest and acknowledgment of the significance of innovative medical technologies aimed at managing chronic pain effectively.
As the medical community continues to seek alternatives to opioid treatments, the potential applications for the technology behind Altius® may expand, giving hope to many individuals struggling with pain following amputations. The successful execution of this financial injection could mark a breakthrough not just for Neuros Medical, but for numerous patients eagerly awaiting effective pain relief options.
With the ever-increasing need for less invasive and non-opioid solutions in healthcare, Neuros Medical positions itself as a frontrunner in creating impactful change within this space. The imminent commercialization of Altius® through the support received could lead to a transformative era in pain management for amputees, ensuring that they can lead more fulfilling lives despite their challenges.
In conclusion, the collaboration between EQT Life Sciences and Neuros Medical signifies a commitment to address an urgent need within the medical field. As funding fuels innovation, the hope is that more patients will soon experience the benefits of advanced therapies, paving the way for a future where pain control is accessible, effective, and life-enhancing.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.